Hosted on MSN

PLSE wins FDA IDE approval to launch nPulse AF ablation study trial

Pulse Biosciences PLSE recently announced that the FDA has granted Investigational Device Exemption (“IDE”) approval to initiate its nPulse Cardiac Catheter Ablation System study for the treatment of ...
Seeking Alpha

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
MedPage Today

Globe Device Touted as Advance for Pulsed Field Ablation

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in paroxysmal atrial fibrillation (Afib). In the single-arm PULSAR IDE study of 162 ...
Healio

All-in-one ablation catheter shows good safety, promise in treating paroxysmal AF

Please provide your email address to receive an email when new articles are posted on . An all-in-one ablation system showed durable pulmonary vein isolation at 1 year. Three-quarters of patients ...
WDAF-TV

CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study

BURLINGTON, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- CoreMap today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to extend ...